Original ResearchFull Report: Clinical-LiverEfficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest These authors disclose the following: Gregory Everson has been on advisory committees or review panels for Roche/Genentech, Merck, and HepC Connection; has been a board member of HepQuant, LLC, and PSC Partners; has performed consulting for Roche/Genentech and Abbott; has received grant/research support from Roche/Genentech, Pharmassett, Vertex, GSK, Schering-Plough, Bristol-Myers Squibb, Tibotec, GlobeImmune, Pfizer, Abbott, Conatus, ZymoGenetics, and PSC Partners; has held a management position for HepQuant, LLC; and has a patent held/filed with the University of Colorado; Maribel Rodriguez-Torres has been a consultant for Akros Pharmaceutical, Bristol-Myers Squibb, Genentech, Hoffman-La Roche, Inhibitex, Janssen R&D Ireland, Merck Sharp & Dohme, Corp, Pharmasset, Santaris Pharma, and Vertex Pharmaceutical, Inc; has received grant/research support from Inhibitex, Johnson & Johnson, Merck Sharp & Dohme, Corp, Mochida Pharmaceutical, Novartis, Pfizer, Pharmasset, Santaris Pharma, A/S, Scynexis, Inc, Siemens Healthcare Diagnostics, Vertex Pharmaceutical, Inc, ZymoGenetics, Abbott Laboratories, Akros Pharmaceutical, Anadys Pharmaceutical, Beckman Coulter, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Pharmaceuticals, Glaxo Smith Kline, Hoffman-La Roche, Human Genome Sciences, Idenix Pharmaceutical, and Idera Pharmaceutical; Christophe Hézode has been compensated for speaking and teaching by Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Corp, Janssen, Abbvie, and Gilead; Eric Lawitz had performed consulting for Theravance; has received grant/research support from Abbott Laboratories, Anadys Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Glaxo-SmithKline, GlobeImmune, Medtronic, Idenix Pharmaceuticals, Idera Pharmaceuticals, Medarex, Merck & Co, Novartis, Roche, Schering-Plough, Pfizer, Vertex Pharmaceuticals, ZymoGenetics, Tibotec/Johnson and Johnson, Pharmasset, Biolex, Achillion Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Inhibitex Pharmaceuticals, Pharmasset, Santaris, and Scynexis Pharmaceuticals; Marc Bourlière has been a member of advisory committees or review panels for Merck; has been a board member of Gilead and Tibotec; has performed consulting for Boehringer Ingelheim, Roche, Schering-Plough, Novartis, Bristol-Myers Squibb, Abbott, and Janssen; Veronique Loustaud-Ratti has been compensated for speaking and teaching by Roche, Schering-Plough, Merck Sharp & Dohme, Corp, Janssen, Bristol-Myers Squibb, and Gilead; and has received grant/research support from Roche and Bristol-Myers Squibb; and has been a board member of Gilead and Roche; Vinod Rustgi has received grant/research support from Gilead, Bristol Myers Squibb, Abbot, Anadys, and Boehringer-Ingelheim; has been compensated for speaking and teaching by Merck, Genentech, and Vertex; Patrick Marcellin has performed consulting for Roche, Gilead, Bristol-Myers Squibb, Vertex, Novartis, Janssen-Tibotec, Merck Sharp & Dohme, Corp, Boehringer, Abbott, and Pfizer; has received grant/research support from Roche, Gilead, Janssen-Tibotec, and Merck Sharp & Dohme, Corp; has been compensated for speaking and teaching by Roche, Gilead, Bristol-Myers Squibb, Vertex, Janssen-Tibotec, Merck Sharp & Dohme, Corp, and Abbott; and is a stock shareholder in Novartis; Stanislas Pol has served as a board member of Sanofi, Bristol-Myers-Squibb, Boehringer Ingelheim, Tibotec Janssen Cilag, Vertex, Gilead, Roche, Merck Sharp & Dohme, Corp, Novartis, and Abbvie; and has been compensated for speaking and teaching by Glaxo Smith Kline; Paul Thuluvath has been a member of advisory committees or review panels for Bayer; has received grant/research support from Bayer, Bristol-Myers Squibb, Boehringer, and Novartis; and has been compensated for speaking and teaching by Bayer/Onyx, Roche, Vertex, and Gilead; Karen Sims, Timothy Eley, Xiaodong Wang, Shu-Pang Huang, Fiona McPhee, Megan Wind-Rotolo, Ellen Chung, Claudio Pasquinelli, Dennis Grasela, and David Gardiner are employees and may be shareholders of Bristol-Myers Squibb. The remaining authors have nothing to disclose.
This study is registered with ClinicalTrials.gov, number NCT01455090, and also is known as study AI443-014.
Funding This study was sponsored by Bristol-Myers Squibb. The study was designed and conducted by the sponsor in collaboration with the principal investigators. The sponsor collected the data, monitored the study conduct, and performed the statistical analyses.
Professional medical writing and editorial assistance was provided by Carolyn Carroll, PhD, an employee of Bristol-Myers Squibb.
Author names in bold designate shared co-first authorship.